WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics

• Best ESG rating tier of negligible-risk with a top 1% global ranking score
• Industry and Regional ESG Top-Rated Company for five consecutive years
• Leader in Green CRDMO to drive innovation for a healthier future

SHANGHAI, July 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has elevated its Morningstar Sustainalytics ESG rating score to the highest negligible-risk tier, demonstrating its leadership in the global pharmaceutical industry.

Sustainalytics is a leading ESG data, research, and ratings firm that supports global investors with their development and implementation of responsible investment strategies. Its 2025 ESG Risk Ratings—covering more than 15,000 companies across different industries worldwide—evaluates over 20 material ESG issues through over 200 indicators and categorizes rating results across five risk levels, from the best negligible to the worst severe.

Under the two-dimensional assessment framework, WuXi Biologics achieved the lowest level of risk exposure and was given the strongest risk management score, placing it in the negligible-risk tier with a top 1% global ranking. In addition, for the fifth consecutive year, the company has been recognized by Morningstar Sustainalytics as an Industry and Regional ESG Top-Rated Company.

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very pleased to have achieved the negligible-risk rating from Morningstar Sustainalytics. It is a reflection of and recognition for WuXi Biologics' continuous commitment to enhancing sustainability capabilities. As a global leader in Green CRDMO, we are focused not only on delivering our own ESG excellence but also on enabling partners worldwide to fulfill their ESG commitments, collaborating with all stakeholders to promote responsible practices throughout the entire value chain."

As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), the company proactively contributes to advocating sustainability and has earned widespread recognitions for its efforts. It has been granted a MSCI AAA rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security "A list" and given an A- CDP Climate Change leadership-level score since 2023; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

About Morningstar Sustainalytics
Morningstar Sustainalytics is a leading ESG data, research, and ratings firm that supports investors around the world with the development and implementation of responsible investment strategies. For more than 30 years, the firm has been at the forefront of developing high-quality, innovative solutions to meet the evolving needs of global investors. Today, Morningstar Sustainalytics works with hundreds of the world's leading asset managers and pension funds who incorporate ESG information and assessments into their investment processes. The firm also works with hundreds of companies and their financial intermediaries to help them consider material sustainability factors in policies, practices, and capital projects. Morningstar Sustainalytics has analysts around the world with varied multidisciplinary expertise across more than 40 industry groups. For more information, visit www.sustainalytics.com.

About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

ESG

[email protected]

Media

[email protected]

SOURCE WuXi Biologics